Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

These Patients Are More Apt to Be Depressed

Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Certain subgroups of patients with hematologic malignancies are more prone to experience distress and depression, researchers concluded after conducting a study involving 246 individuals. Participants with hematologic malignancies completed the Patient Health Questionnaire 9 (PHQ-9) and Distress Thermometer (DT) prior to receiving outpatient parenteral chemotherapy. Among the results:

  • PHQ-9 score of ≥ 9 and DT score ≥ 4 pointed to a high risk of major depression and distress.
  • PHQ-9 score ≥ 9 was linked with living alone, positive PHQ-2, and high Charlson comorbidity index.
  • DT score ≥4 was linked with being married and female.

The authors noted that at-risk subgroups should be aggressively screened even in the absence of universal screening programs.


Shreders A, Niazi S. Hodge D, et al. Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies. [Published online ahead of print December 7, 2017]. Ann Hematol. doi:10.1007/s00277-017-3198-0.

This Week's Must Reads

HCV Screening Program in a Large Birth Cohort, Open Forum Infect Dis; ePub 2018 Mar 26; Cornett, et al

Do Electronic Reminders Aid in HCV Screening?, J Viral Hepat; ePub 2018 Mar 30; MacLean, et al

HCV Screening Shows Minimal Increase Overall , Cancer Epidemiol Biomarkers Prev; 2018 Apr; Kasting, et al

Improving Access to HCV Medications, J Manag Care Spec Pharm; 2018 Apr; Vu, et al

Previous HBV & Clinical Outcomes in HCV, J Viral Hepat; ePub 2018 Mar 25; Wang, et al

Must Reads in Hematologic Malignancies

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al

Tyrosine Kinase Inhibitors in Pediatric ALL, Hematology 2017; 2017 Dec 8; Silverman, et al